Embed or link this publication


Academic Industry Roundtable

Popular Pages

p. 1



p. 2



p. 3



p. 4

C L I N I C A L A N D T R A N S L AT I O N A L R E S E A R C H TABLE OF CONTENTS 6 8 10 25 28 30 50 51 54 Agenda and Locations Keynote Speakers - Day One Roundtables - Day One Networking Reception Keynote Speakers - Day Two Roundtables - Day Two About SUNY Global Center Maps Notes 4


p. 5

C L I N I C A L A N D T R A N S L AT I O N A L R E S E A R C H WELCOME MESSAGE I am so pleased to welcome you to the inaugural SUNY Academic Industry Round Table (SUNY AIR). This event brings together some of the best research faculty from across SUNY’s 64 campuses with industry innovators from across the globe. SUNY AIR is a strategic initiative of State University of New York designed to catalyze academy/industry partnerships, building on SUNY’s existing successes in this area. Academia and industry each have different but complimentary perspectives and skill sets that can be leveraged to solve critical problems facing our society. As part of SUNY’s commitment to increase its impact on State and global challenges, SUNY AIR is designed to foster positive, productive relationships among faculty, students and industry. The inaugural 2016 SUNY AIR is dedicated to clinical and translational research. This is a sector that faces some challenges but also tremendous opportunity. Through our discussions over the next two days, SUNY AIR seeks to open a dialog about how best to improve access to early discoveries, innovate through creative alliances, foster applied learning opportunities for SUNY students, and engage in public/private partnerships. My thanks to all of our panelists and speakers for sharing their time and expertise. And my thanks and appreciation to all of our attendees for participating in this important conversation. My goal for this event is that we all come away with important information about how best to move forward together. I look forward to seeing you at SUNY AIR 2016! ALEXANDER N. CARTWRIGHT, PhD Provost and Executive Vice Chancellor, State University of New York Interim President, Research Foundation for SUNY | 5


p. 6

C L I N I C A L A N D T R A N S L AT I O N A L R E S E A R C H SUNY Academic Industry Roundtables Day One JAN UA RY 27, 201 6 AGENDA 9:00am - 10:00am REGISTRATION WELCOME OPENING REMARKS KEYNOTE ADDRESS OPENING ROUNDTABLE LUNCH A F T E R N O O N R O U N D T A B L E S 10:00am - 10:10am H. Carl McCall 10:10am - 10:20am Alexander Cartwright, PhD 10:20am - 11:00am Craig Lipset 11:00am - 12:15pm Clinical and Translational Research at SUNY 12:15pm - 1:00pm 1:15pm - 2:30pm DATA IN CLINICAL AND TRANSLATIONAL RESEARCH AT SUNY - GC1 STUDENT SUCCESS - MP1 2:30pm - 2:45pm BREAK PRECISION MEDICINE - GC2 Sponsored by Metabolon 2:45pm - 4:00pm COGNITIVE COMPUTING - MP2 DEVELOPING AND MANAGING ALLIANCES - MP3 Sponsored by Elsevier 4:05pm - 5:15pm DIABETES - GC3 6:00pm - 8:00pm NETWORKING RECEPTION Waldorf Astoria Sponsored by Metabolon 6


p. 7

C L I N I C A L A N D T R A N S L AT I O N A L R E S E A R C H SUNY AIR AGENDA SUNY Academic Industry Roundtables Day Two JA NUA RY 28 , 201 6 AGENDA 7:45am - 8:45am BREAKFAST OPENING REMARKS KEYNOTE ADDRESS Sponsored by Forte M O R N I N G 8:10am - 8:15am Angelo Fatta, PhD 8:15am - 8:30am Srini Kalluri R O U N D T A B L E S 8:30am - 9:45am REGENERATIVE MEDICINE - GC4 WORKFORCE DEVELOPMENT - MP4 9:45am - 10:00am BREAK ALZHEIMER’S DISEASE - GC5 UNEXPECTED COLLABORATIONS THROUGH ANALYTICS - MP6 10:00am - 11:10am 11:15am - 12:30pm GLOBAL HEALTH - GC6 12:30pm - 1:00pm LUNCH A F T E R N O O N R O U N D T A B L E S 1:00pm - 2:30pm INVESTING IN THE NEXT GENERATION OF STARTUPS - GC7 THE IRB: FINDING COMMON GROUND - MP7 Bryan Allinson 2:30pm - 2:45pm CLOSING REMARKS Conference Key GLOBAL CLASSROOM - GC MULTIPURPOSE ROOM - MP | 7


p. 8

JANUARY 27 | 10:00am - 10:10am | GLOBAL CLASSROOM WELCOME H. Carl McCall Chairman, Board of Trustees State University of New York H. Carl McCall was appointed Chairman of the State University of New York Board of Trustees October 17, 2011. He first joined the Board as a member on October 22, 2007. Mr. McCall served as Comptroller of the State of New York from May 1993 to December 2002. As Chief Fiscal Officer of the State, he was responsible for governmental and financial oversight and pension fund management. As sole Trustee of the 880,000-member State and Local Retirement Systems, Mr. McCall was responsible for investing a pension fund valued at $120 billion. Mr. McCall has had a distinguished career as a public servant. He served three terms as a New York State Senator representing the upper Manhattan district of New York City; as an Ambassador to the United Nations; as a Commissioner of the Port Authority of New York and New Jersey; and as the Commissioner of the New York State Division of Human Rights. 8


p. 9

JANUARY 27 | 10:20am - 11:00am | GLOBAL CLASSROOM KEYNOTE ADDRESS I Craig H. Lipset Head of Clinical Innovation Pfizer Craig Lipset, Head of Clinical Innovation within Worldwide Research and Development at Pfizer, challenges SUNY to be disruptive. As the SUNY system contemplates how to systematize clinical research, it will find itself at the precipice of an incredible opportunity. Mr. Lipset will describe how the diversity of the population of New York State – a differentiating asset – can be leveraged through robust data infrastructure, experienced personnel, efficient processes, and a culture of collaboration. He will describe why investing in the infrastructure to collect data in remarkable new ways – and event capture the elusive “referral unicorn” – will allow SUNY to conduct clinical studies in a radically different and more efficient way. | 9


p. 10

C L I N I C A L A N D T R A N S L AT I O N A L R E S E A R C H 11:00am - 12:15pm • G LOBA L C L A SSROO M Clinical and Translational Research at SUNY OPENING ROUNDTABLE M O D E R A T O R Provost and Executive Vice Chancellor State University of New York Interim President Research Foundation for SUNY Alexander N. Cartwright, PhD Founder and President Bio Signal Corporation André Fenton is a recognized neuroscientist, biomedical engineer and entrepreneur working on three related problems: how brains store information in memory; how brains coordinate knowledge to selectively activate relevant information and suppress irrelevant information; and how to record electrical activity from brain cells in freely-moving subjects. His lab recordings of electrical brain activity are elucidating the physiology of cognitive control and cognitive dysfunction in schizophrenia. Dr. Fenton is a Professor at the Center for Neural Science at New York University and Associate Professor of Physiology and Pharmacology at SUNY Downstate Medical Center. Dr. Fenton and colleagues identified PKMzeta as the first molecule that maintains the persistence of memories in the brain, a discovery recognized by Science Magazine as one of the 10 most important breakthroughs in all of science and technology published in 2006. André Fenton, PhD Senior Director Janssen Pharmaceuticals Karin Gulbrandsen is a Senior Director within Trial Coordination and Site Management for Janssen Pharmaceuticals Research and Development. As the U.S. Head, Karin is responsible for driving the delivery of studies in all phases of clinical development across therapeutic areas that include Oncology, Cardiovascular, Metabolism, Infectious Disease, Neuroscience, Immunology and Vaccines. In Karin’s 20+ years of experience in the pharmaceutical business, she has served as a CRA, Lead CRA, Trainer, CRA and Department Manager as well as Regional and Global Leads for multiple projects and initiatives. Karin believes in focusing efforts on continuous improvement in order to continue to streamline the ways we develop and deliver high quality medicines for the patients that are waiting. Karin Gulbrandsen DAY ONE JAN. 27 Dr. Alexander N. Cartwright is SUNY Provost and Executive Vice Chancellor and Interim President of the Research Foundation for SUNY. He supports the Chancellor and Board of Trustees in the oversight of the 64-campus system and also oversees the Research Foundation’s management of over $1 billion dollars in annual sponsored research activity. He most recently served as the University at Buffalo Vice President for Research and Economic Development, and Acting Executive Director of the NYS Center of Excellence in Bioinformatics and Life Sciences. He continues to serve as a UB faculty member. An internationally recognized researcher and scholar in the area of optical sensors, Dr. Cartwright holds six patents and his work has been licensed by three startup companies. He was recently named a fellow in the National Academy of Inventors. In addition, Dr. Cartwright is a Fellow of SPIE, a senior member of IEEE, a member of AAAS, ASEE, Eta Kappa Nu and the Materials Research Society (MRS). His PhD is from the University of Iowa. D 10 I S C U S S I O N L E A D E R S


p. 11

C L I N I C A L A N D T R A N S L AT I O N A L R E S E A R C H DAY ONE JANUARY 27 , 2016 11:00am - 12:15pm • G LOBA L C L A SSROO M SUNY System and campus leaders will join industry experts in a discussion about SUNY’s innovation, research, and partnering goals, as well as how to achieve them. The panel will introduce major topics, including alliance management, clinical trial infrastructure, and innovative preclinical research, that will be discussed throughout the duration of the event. Product Manager US Army Medical Research and Materiel Command Mr. Jasper is a Product Manager (PdM) in the Pharmaceutical Systems Program Management Office (PSPMO) of the U.S. Army Medical Research and Materiel Command (USAMRMC), Ft. Detrick, Maryland. As a PdM, his primary responsibility is to lead DoD medical product development teams. Since 2009, Mr. Jasper’s primary responsibility has been to serve as the Chair of the USAMRMC Dengue Vaccine Program. Additionally, he has either led or served several other Integrated Product Teams (IPTs) to include: the Rapid Diagnostics and Detection Devices, Alternate Arthropod Repellent, Leishmania Rapid Diagnostic Device, Dengue Rapid Diagnostic Device, Hepatitis E vaccine, and Chikungunya vaccine. Through these efforts, Mr. Jasper’s goal is to develop and field products for US Service Members. However, this goal parallels the need to develop infectious disease medical products for global health. He holds a B.S. in Mechanical Engineering and an M.S. in Engineering Management; inclusive of Biomechanics and Manufacturing Design. In addition, Mr. Jasper holds a graduate certificate in Regulatory Compliance for Biotechnology Products. Louis Jasper Head of Clinical Innovation Pfizer Craig H. Lipset is Head of Clinical Innovation within Worldwide Research and Development at Pfizer. Craig’s team is responsible for impacting clinical research through digital tools, innovative research approaches and unprecedented collaborations. He serves on the Board of Directors for the Foundation for Sarcoidosis Research, the Board of Directors for the MedStar Health Research Institute, the Operations Committee for TransCelerate BioPharma, and as a Mentor at health tech accelerator Blueprint Health. Craig also serves on the Editorial Board for Therapeutic Innovation and Regulatory Science. Craig previously served as Venture Partner in Pfizer Venture Investments as well as Senior Director in Molecular Medicine within Pfizer RandD. Prior to Pfizer he served as Associate Vice President of Program Management at Adnexus Therapeutics (acquired by Bristol-Myers Squibb), and on the founding management team for Perceptive Informatics (now part of PAREXEL International). Craig H. Lipset SUNY Distinguished Professor; Director, Clinical and Translational Research Center University at Buffalo Timothy F. Murphy MD is SUNY Distinguished Professor of Medicine and Microbiology at the University at Buffalo, State University of New York. Dr. Murphy’s research interests include vaccine development for bacteria that cause ear infections in children and also infections in people with chronic obstructive pulmonary disease (COPD). He is internationally recognized for his research, which is funded by the National Institutes of Health. After serving for 16 years as UB Chief of Infectious Diseases, Dr. Murphy was appointed Director of the UB Clinical and Translational Research Center, a state-of-the-art research center of the UB School of Medicine that opened in 2012 on the Buffalo Niagara Medical Campus. The Center houses a clinical research center and laboratories of leading scientists who lead teams of researchers to perform translational research with a vision toward making new discoveries to improve healthcare for people in Western New York and the nation. Timothy F. Murphy, MD Kathryn Richdale, OD, PhD Assistant Clinical Professor College of Optometry Dr. Kathryn Richdale is an Assistant Professor and the founding Director of the Clinical Vision Research Center at the SUNY College of Optometry. She received her OD, PhD, and Cornea and Contact Lens Fellowship from The Ohio State University. She has been a principal investigator for industryand federally-funded research in presbyopia, cornea, and contact lenses. She has been awarded an American Optometric Foundation Ezell Fellowship, Prevent Blindness Ohio Young Investigator Fellowship and Ohio Lions Eye Research Fellowship, and is the inaugural Alden N. Haffner Innovation Chair at SUNY Optometry. Dr. Richdale served as a 2014-15 SUNY Research Foundation Presidential Fellow. D I S C U S S I O N L E A D E R S 11 |


p. 12

C L I N I C A L A N D T R A N S L AT I O N A L R E S E A R C H 1:15pm - 2:30pm • G LOBA L C L A SSROO M Data in Clinical and Translational Research at SUNY ROUNDTABLE GC1 M O D E R A T O R Vice President, Real World Data and Analytics Pfizer Vice President, Real World Data and Analytics (RWDnA) in the Global Health and Value group at Pfizer, Inc. Marc has held senior-level positions in industry including Executive Vice President and Senior Scientist at OptumInsight; Vice President, Global Health Outcomes at Eli Lilly and Company; and Vice President, Outcomes Research and Management at Merck and Co., Inc. Marc has served on the Medicare Evidence Development and Coverage Advisory Committee (MedCAC) for CMS, the steering committee for the AHRQ Centers for Research and Education on Therapeutics (CERTs), the board of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), the Advisory Council for North America (ACNA) of the DIA, and the editorial advisory board of Value in Health. Currently, he serves as chair of the Innovative Technology Advocacy Committee of PhRMA. Marc Berger, MD Piraye Yurttas Beim, PhD Founder, Director and Chief Executive Officer Celmatix, Inc. Associate Vice President of Strategic Initiatives Geisinger Health System Kimberly Eck, PhD, Associate Vice President, Resource Development, leads the Office of Competitive Grants in the pursuit of external funding sources and strategic partnerships. Before joining Geisinger, Dr. Eck held a research development position in the central office of The Research Foundation for the State University of New York (SUNY) in Albany, NY. There, she led research development programming and industry engagement initiatives. She successfully facilitated the formation of research teams and development of large, multidisciplinary proposals requesting more than $180M. Acknowledging her contributions, she was accepted into the inaugural class of The Research Foundation for SUNY’s Leadership Academy in 2015. Dr. Eck’s doctoral degree is in epidemiology. She is a Clinical Assistant Professor in the Department of Health Policy, Management, and Behavior at the School of Public Health at the University at Albany. Kimberly Eck, PhD Leslie Hyman, PhD Head, Division of Epidemiology and Biostatistics, Department of Family, Population and Preventive Medicine Stony Brook University Regarded as an expert in female infertility, Dr. Beim’s embryology research at the University of Cambridge (UK) and doctoral work at WeillCornell (NYC) on the molecular genetics of mammalian fertility took a very personal turn when she began to notice many of the successful and career-minded women in her network begin to voice strong concerns about their biological clocks. That is when it dawned on her: What if women could understand their own fertility based on data and biology rather than age alone? How would that change how women made lifedefining decisions? In that moment, Celmatix was born. Dr. Beim has also been widely recognized as an emerging business leader. She was most recently named a NYC Venture Fellow by the NYCEDC and to Crain’s 40 Under 40. She lives in New York City with her husband and sons. Dr. Hyman is Professor of Preventive Medicine and Ophthalmology and Head of the Division of Epidemiology, Department of Family, Population and Preventive Medicine, School of Medicine, Stony Brook Medicine, Stony Brook, New York. She is an ocular epidemiologist with expertise in observational epidemiologic studies and clinical trials. Her research has focused on identifying causes, risk factors and treatment of the leading causes of visual impairment and blindness. She is the Principal Investigator for the Coordinating Center for two NIH supported multicenter studies- the “Correction of Myopia Evaluation Trial (COMET)/ Collaborative Observational Study of Myopia Progression in COMET Children(COMSICC)”, and the Diabetes and Periodontal Therapy Trial (DPTT). She also served as the co-principal Investigator for the Data Center for the Early Manifest Glaucoma Trial (EMGT), principal investigator for 2 large case-control studies investigating risk factors for age-related macular degeneration and a co-investigator for the Barbados Eye Studies. D 12 I S C U S S I O N L E A D E R S


p. 13

C L I N I C A L A N D T R A N S L AT I O N A L R E S E A R C H DAY ONE JANUARY 27 , 2016 1:15pm - 2:30pm • GLOBA L C L A SSROO M More than 90% of all the data in the world has been generated over the last two years. In this age of big data, organizations must be able to fully utilize all sources of data to make timely, informed decisions. Join us for a discussion on how data can be managed, shared, analyzed, and visualized in support of clinical and translational research at SUNY. Peter Vanderminden, MBA Senior Industry Analyst, IoT Digital Supply Chain Flatiron Strategies Jean Wactawski-Wende, PhD Dean, School of Public Health and Health Professions; Professor, Department of Epidemiology and Environmental Health Peter Winkelstein, MD, MS, MBA, FAAP Executive Director, Institute for Healthcare Informatics Peter Vanderminden, Senior Industry Advisor, IoT, to Flatiron Strategies and CTO at KulaGuna Consulting, Peter Vanderminden advises alternative investment bankers on the IoT industry and consults to companies in the industrial manufacturing, transportation and health-life sciences sectors, helping them to develop enterprise architecture and innovation strategies to integrate physical and digital supply chains for IoT enablement. He serves on the APICS Board of Directors, the leading industry trade association for supply chain management best practices and certifications. He also serves as a member of Rensselaer Polytechnic Institute’s (RPI) Industry Advisory Board on supply chain management and analytics graduate programs at the Lally School of Business and represents RPI to the Industrial Internet Consortium (IIC). He holds an MBA, with Distinction, from Leeds University, Leeds, UK; a BS in Communications Science from RPI, Troy, NY and a post-graduate certificate in System Dynamics from MIT, Cambridge, MA. University at Buffalo Jean Wactawski-Wende, PhD, is an epidemiologist who focuses her research on understanding factors that influence women’s health. With more than 25 years of research experience, she is currently the principal investigator of UB’s Women’s Health Initiative (WHI) Center and also leads the WHI Northeast Regional Center, comprising nine other institutions. Initiated in 1993, the WHI is an NIH-funded, multi-centered study that involves both randomized clinical trials and an observational longitudinal study examining the major factors influencing morbidity and mortality in older women. She has served in various leadership roles in WHI, including publications chair, and the WHI executive committee and is currently serving as the national Chair of the WHI Steering Committee. Results of that work have been far reaching, impacting our understanding of long-term health in older women. University at Buffalo Dr. Peter Winkelstein is a physician executive with extensive experience in medical management, medical informatics – including big data and data science − financial analysis and computer modeling. He serves as the executive director of the University at Buffalo (UB) Institute for Healthcare Informatics (IHI). The IHI supports big data healthcare research at UB and its partners by providing a secure computing environment, data science and security consulting, and extensive healthcare datasets. The IHI opened in 2012 with funding through portions of $25 million in NYS HEAL grants. The IHI is located in the heart of the Buffalo Niagara Medical Campus and provides a secure data center with a state-of-the-art data repository infrastructure with >1M patient records. The IHI is a principal component of the $50 million NYS Buffalo Institute for Genomics and Data Analytics (BIG). Dr. Winkelstein also serves as chief medical informatics officer (CMIO) of UBMD, a multispecialty faculty practice of over 500 UB physicians, and as CMIO of Kaleida Health, the largest health care provider in Western New York with over 1200 hospital beds. D I S C U S S I O N L E A D E R S | 13 #SUNYAIR


p. 14

C L I N I C A L A N D T R A N S L AT I O N A L R E S E A R C H 1:15pm - 2:30pm • M U LT I P U R PO SE ROOM Student Success ROUNDTABLE MP1 C O - M O D E R A T O R C O - M O D E R A T O R Project Coordinator, STEM Start Programs, Department of Technology and Society Stony Brook University After graduating from Stony Brook University with a Bachelor of Arts in Anthropology, Lauren’s career in higher education at Stony Brook began in the nonprofit conservation organization the Institute for Conservation of Tropical Environments (ICTE), within the Department of Anthropology. This environment grew Lauren’s skills for grant writing, submission, and management. In addition, this allowed Lauren to build her proficiencies in research administration, as well as program development. After a twelve year tenure at ICTE, Lauren transitioned to the Department of Technology and Society. She is the coordinator of STEM Smart programs, i.e. OEDG-GeoPREP (Opportunities for Enhancing Diversity in the Geosciences), S-STEM (Scholarships in Science, Technology, Engineering and Mathematics), LSAMP (Louis Stokes Alliance for Minority Participation), NASA New York Space Grant Lauren was accepted in the first cohort of the Research Foundation Leadership Academy. This 15-month program is a professional development opportunity for the enhancement of competencies for employees working in research administration. Lauren Donovan Assistant Dean for Public Engagement, CAS and Director, UHS University at Albany Debernee S. Privott (Deb) is the Assistant Dean for Public Engagement for the College of Arts & Sciences, and also serves as the Director of the University in the High School Program at the University at Albany and Faculty Advisor for UAlbany’s Leaders in Service Program, which she and her husband, Jay Privott, developed in 2009, with the extensive support of the Division of Student Affairs within the Department of Residential Life. Deb is an Assistant Girl Scout Troop Leader in the Capital Region and a member of the SUNY RF Leadership Academy Class of 2016. She is also a member of Spelman College’s Team of Alumnae Recruiters. Deb enjoys teaching an applied learning course that she developed through the University at Albany’s top ranked School of Criminal Justice, where she earned her M.A. and Ph.D. She encourages faculty members and students to explore applied learning opportunities. Debernee Privott, PhD Student Stony Brook University Juan is a senior at Stony Brook University studying Biomedical Engineering with a molecular and cellular engineering specialization. He is currently working on a research project in Dr. Sitharaman’s lab, investigating a non-pharmacological solution to bone loss and bone fracture healing using photoacoustic stimulation. In addition, he has been involved as a mentor in the College of Engineering and Applied Sciences Mentoring Program and as a campus tour guide. He also was part of the SUNY Brain Summer Scholars Program of 2015. Juan likes to play soccer, guitar and chess. Juan Bastidas Adam R. Blanden, MD, PhD Student Upstate Medical University Adam R. Blanden is a 5th year MD/ PhD candidate at Upstate Medical University, a NIH pre-doctoral fellow, and co-founder of Finger Lakes Bio, LLC. A graduate of Binghamton University and former Goldwater Scholar, Adam’s current research focuses on the structure of tumor suppressor p53, with an emphasis on developing new drugs to target the protein. This work has led to the definition of a new class of p53-targeting molecules called synthetic metallochaperones, multiple peer-reviewed publications, 7 licensed patent applications, and a large venturebacked investment in his academic lab to develop compounds to bring to human clinical trials -- an initiative that will be executed along with collaborators at the Cancer Institute of New Jersey. Adam co-founded Finger Lakes Bio along with fellow graduate student Aaron J. Wolfe in June of 2015 to enable and execute previously impossible p53 drug discovery initiatives. Using a patent-pending protein production technology Adam developed during his graduate research, Finger Lakes Bio can produce the full-length bioactive p53 molecule. D 14 I S C U S S I O N L E A D E R S


p. 15

C L I N I C A L A N D T R A N S L AT I O N A L R E S E A R C H DAY ONE JANUARY 27 , 2016 1:15pm - 2:30pm • M U LT I P U R PO SE ROOM There is no question that Chancellor Nancy L. Zimpher is focused on students. At SUNY, her student success equation (Access + Completion = Success) is more than a mantra, it is the vision driving initiatives on all of SUNY’s 64 campuses. Applied learning experiences, such as student internships, co-ops, and research, are critical aspects of enabling students to complete their degrees and go on to be successful, productive employees. It is understandable that Chancellor Zimpher has set a goal of 100% of SUNY students participating in applied learning experiences. Join us for this discussion about how industry and SUNY can strengthen their participation in the student success equation and get the students’ perspectives on the importance of applied learning experiences. Director, Neuroscience, Postdoctoral Program Director Regeneron Pharmaceuticals Susan Croll received her BA from SUNY Geneseo followed by a PhD in Neuropsychology from the Graduate Center of the City University of New York (CUNY). From 1992-2001, she worked as a postdoctoral fellow and then as a scientist at Regeneron Pharmaceuticals, where she studied the therapeutic potential of protein growth factors. In 2001, Susan left her full-time position at Regeneron after nine productive years, including 15 publications, to begin an academic career. She started her own laboratory at Queens College of CUNY where she undertook a focused study of the effects of the growth factors BDNF and VEGF in epilepsy and other neurological diseases. While there, she published 20 articles and one book, obtained NIH funding, won awards for her classroom teaching, spearheaded the establishment of a research-based Neuroscience major, and secured tenure. Throughout her time in academia, she maintained her association with Regeneron, continuing as a consulting scientist. Susan D. Croll, PhD Student Stony Brook University Kamal James is a senior undergraduate at Stony Brook University majoring in Biomedical Engineering with a specialization in Biomechanics/Biomaterials, expected to graduate this May. As a member of LSAMP, Kamal has had the pleasure of learning about the SUNY RF research program for undergraduate students. Since Fall 2012, Kamal has worked within the BME department as a research assistant, and this past September joined a lab headed by Dr. Yi-Xian Qin. Part of their research is done on developing ultrasound technologies to enhance diagnosis of metabolic bone diseases. Prior to that Kamal was an assistant in Dr. Sitharaman’s lab, where he helped to complete a study on bone tissue engineering applications of carbon nanomaterials. This past summer Kamal had his first summer internship at Nanoprobes in Yaphank, NY, where he synthesized silica-gold nanoshells for NRT (nanogold radiation therapy) for brain cancer, under the supervision of Dr. James F. Hainfeld. Overall Kamal attributes his thorough undergraduate research experience to the great mentors and advisors who encouraged him to pursue his absolute potential. Kamal James Professor Department of Chemistry University at Albany Igor K. Lednev is a professor at the University at Albany, State University of New York. Graduating from the Moscow Institute of Physics and Technology, Russian Federation, he received his Ph.D. in 1983. Dr. Lednev then held a position as a group leader at the Institute of Chemical Physics, Russian Academy of Sciences. As an academic visitor, he worked in several leading laboratories around the world in countries including the United Kingdom, Japan, Canada and Germany. In 1997, Dr. Lednev came to the US and joined the University of Pittsburgh as a research professor, until moving to the University at Albany in 2002. Dr. Lednev’s research is focused on the development and application of novel laser spectroscopy for biomedical research and forensic purposes. To name a few accomplishments, Dr. Lednev built a new instrument that allowed for discovering a new type of protein folding-aggregation phenomenon, spontaneous refolding of amyloid fibrils. Igor Lednev, PhD Founder and President Theragnostic Technologies and Millennial Materials Inc. Associate Professor, Department of Biomedical Engineering Stony Brook University Balaji Sitharaman is an Associate Professor of Biomedical Engineering at Stony Brook University. He received his B.S. (2000) from the Indian Institute of Technology at Kharagpur. He received his M.A and Ph.D. (2005) from Rice University, where he also completed his postdoctoral research (2005-2007) as the J. Evan Attwell-Welch Postdoctoral Fellow at the Richard E. Smalley Institute for Nanoscale Science and Technology. Sitharaman’s research program is at the interface of nanotechnology, regenerative and molecular medicine. His lab synergizes the advancements in each of these fields to tackle problems related to diagnosis and treatment of disease and tissue regeneration. He is the founder and director of two start ups Theragnostic Technologies Inc. and Millennial Materials Inc. - that are commercializing the inventions arising out of his laboratory. Balaji Sitharaman, PhD D I S C U S S I O N L E A D E R S 15 |



no comments yet